Affibody Progresses Lead Asset To Phase II in Uveitis

IL-17 blocker izokibep targets autoimmune diseases

 
• By Sten Stovall
  
Uveitis Diagnosis
Affibody CEO Says Uveitis Represents Big Commercial Opportunity • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D